1
|
Vega-Castro A, Rodríguez-Gil D, Martínez-Gomariz M, Gallego R, Peña MI, Palacios R. Api m 6 and Api m 10 as Major Allergens in Patients With Honeybee Venom Allergy. J Investig Allergol Clin Immunol 2022; 32:116-123. [PMID: 32856591 DOI: 10.18176/jiaci.0639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Component-resolved diagnosis plays a key role in the diagnosis and treatment of honeybee venom allergy (HVA). Our aim was to study whether any of the allergens not included in the usual diagnostic platforms are relevant in our population. MATERIAL AND METHODS The allergenic sensitization profile of Spanish patients who experienced a systemic reaction after a honeybee sting and were diagnosed with HVA was studied by immunoblotting based on raw autochthonous Apis mellifera venom characterized using SDS-PAGE and mass spectrometry and a commercial assay (ImmunoCAP). RESULTS Allergens in the International Union of Immunological Societies database were detected in the raw A mellifera venom extract used, except Api m 12. Sera from 51 patients with a median (IQR) age of 46.2 years (35.6-54.6) were analyzed. ImmunoCAP revealed Api m 1 and Api m 10 to be major allergens (88.2% and 74.5%, respectively). Moreover, Api m 6 (85.4%) was detected by immunoblotting. CONCLUSION Api m 1, Api m 6, and Api m 10 are major A mellifera venom allergens in our population.
Collapse
Affiliation(s)
- A Vega-Castro
- Hospital Universitario de Guadalajara, Guadalajara, Spain; Spanish Thematic Network and Co-operative Research Centre ARADyAL, Center RD16/0006/0023
| | | | | | - R Gallego
- Diater Laboratorios S.A., Leganés, Madrid, Spain
| | - M I Peña
- Hospital Universitario de Guadalajara, Guadalajara, Spain; Spanish Thematic Network and Co-operative Research Centre ARADyAL, Center RD16/0006/0023
| | - R Palacios
- Diater Laboratorios S.A., Leganés, Madrid, Spain
| |
Collapse
|
2
|
Soler G, Legido R, Perez X, Martinez-Villacampa M, Santos C, Losa F, Ruffinelli J, Mulet N, Teule A, Castany R, Gallego R, Carbonell M, Manzana A, Rios A, Saldaña J, Salazar R. 513P Prospective evaluation of the G8 screening tool for predicting survival in elderly patients with colon cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Seguí E, Alonso-Orduna V, Sesma A, Martin-Richard M, Salud A, Fernández-Montes A, Fernández-Martos C, Ruiz-Casado A, Gallego J, Aparicio J, Gálvez E, Manzano H, Alcaide-Garcia J, Gallego R, Falco E, Esposito F, Oliveres H, Torres F, Feliu J, Maurel J. 471P Identification and validation of a new prognostic score in metastatic colorectal cancer (mCRC): GEMCAD score. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Al-Massadi O, Quiñones M, Clasadonte J, Hernandez-Bautista R, Romero-Picó A, Folgueira C, Morgan DA, Kalló I, Heras V, Senra A, Funderburk SC, Krashes MJ, Souto Y, Fidalgo M, Luquet S, Chee MJ, Imbernon M, Beiroa D, García-Caballero L, Gallego R, Lam BYH, Yeo G, Lopez M, Liposits Z, Rahmouni K, Prevot V, Dieguez C, Nogueiras R. MCH Regulates SIRT1/FoxO1 and Reduces POMC Neuronal Activity to Induce Hyperphagia, Adiposity, and Glucose Intolerance. Diabetes 2019; 68:2210-2222. [PMID: 31530579 PMCID: PMC6868473 DOI: 10.2337/db19-0029] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 09/03/2019] [Indexed: 12/20/2022]
Abstract
Melanin-concentrating hormone (MCH) is an important regulator of food intake, glucose metabolism, and adiposity. However, the mechanisms mediating these actions remain largely unknown. We used pharmacological and genetic approaches to show that the sirtuin 1 (SIRT1)/FoxO1 signaling pathway in the hypothalamic arcuate nucleus (ARC) mediates MCH-induced feeding, adiposity, and glucose intolerance. MCH reduces proopiomelanocortin (POMC) neuronal activity, and the SIRT1/FoxO1 pathway regulates the inhibitory effect of MCH on POMC expression. Remarkably, the metabolic actions of MCH are compromised in mice lacking SIRT1 specifically in POMC neurons. Of note, the actions of MCH are independent of agouti-related peptide (AgRP) neurons because inhibition of γ-aminobutyric acid receptor in the ARC did not prevent the orexigenic action of MCH, and the hypophagic effect of MCH silencing was maintained after chemogenetic stimulation of AgRP neurons. Central SIRT1 is required for MCH-induced weight gain through its actions on the sympathetic nervous system. The central MCH knockdown causes hypophagia and weight loss in diet-induced obese wild-type mice; however, these effects were abolished in mice overexpressing SIRT1 fed a high-fat diet. These data reveal the neuronal basis for the effects of MCH on food intake, body weight, and glucose metabolism and highlight the relevance of SIRT1/FoxO1 pathway in obesity.
Collapse
Affiliation(s)
- Omar Al-Massadi
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Mar Quiñones
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Jerome Clasadonte
- INSERM, U1172, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Center, Lille, France
- FHU 1000 Days for Health, School of Medicine, University of Lille, Lille, France
| | - René Hernandez-Bautista
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | - Amparo Romero-Picó
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Cintia Folgueira
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Donald A Morgan
- Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, and Iowa City VA Health Care System, Iowa City, IA
| | - Imre Kalló
- Laboratory of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary
| | - Violeta Heras
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Ana Senra
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | - Samuel C Funderburk
- Diabetes, Endocrinology, and Obesity Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
| | - Michael J Krashes
- Diabetes, Endocrinology, and Obesity Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
| | - Yara Souto
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | - Miguel Fidalgo
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | - Serge Luquet
- Unité de Biologie Fonctionnelle et Adaptative, CNRS UMR 8251, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Melissa J Chee
- Division of Endocrinology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA
| | - Monica Imbernon
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
- INSERM, U1172, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Center, Lille, France
| | - Daniel Beiroa
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Lucía García-Caballero
- Department of Morphological Sciences, School of Medicine, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | - Rosalia Gallego
- Department of Morphological Sciences, School of Medicine, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
| | - Brian Y H Lam
- MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, and Addenbrooke's Hospital, Cambridge, U.K
| | - Giles Yeo
- MRC Metabolic Diseases Unit, Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, and Addenbrooke's Hospital, Cambridge, U.K
| | - Miguel Lopez
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Zsolt Liposits
- Laboratory of Endocrine Neurobiology, Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary
| | - Kamal Rahmouni
- Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, and Iowa City VA Health Care System, Iowa City, IA
| | - Vincent Prevot
- INSERM, U1172, Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Center, Lille, France
- FHU 1000 Days for Health, School of Medicine, University of Lille, Lille, France
| | - Carlos Dieguez
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| | - Ruben Nogueiras
- Department of Physiology, CIMUS, Universidad de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición, Santiago de Compostela, Spain
| |
Collapse
|
5
|
Folgueira C, Beiroa D, Porteiro B, Duquenne M, Puighermanal E, Fondevila MF, Barja-Fernández S, Gallego R, Hernández-Bautista R, Castelao C, Senra A, Seoane P, Gómez N, Aguiar P, Guallar D, Fidalgo M, Romero-Pico A, Adan R, Blouet C, Labandeira-García JL, Jeanrenaud F, Kallo I, Liposits Z, Salvador J, Prevot V, Dieguez C, Lopez M, Valjent E, Frühbeck G, Seoane LM, Nogueiras R. Hypothalamic dopamine signaling regulates brown fat thermogenesis. Nat Metab 2019; 1:811-829. [PMID: 31579887 PMCID: PMC6774781 DOI: 10.1038/s42255-019-0099-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Dopamine signaling is a crucial part of the brain reward system and can affect feeding behavior. Dopamine receptors are also expressed in the hypothalamus, which is known to control energy metabolism in peripheral tissues. Here we show that pharmacological or chemogenetic stimulation of dopamine receptor 2 (D2R) expressing cells in the lateral hypothalamic area (LHA) and the zona incerta (ZI) decreases body weight and stimulates brown fat activity in rodents in a feeding-independent manner. LHA/ZI D2R stimulation requires an intact sympathetic nervous system and orexin system to exert its action and involves inhibition of PI3K in the LHA/ZI. We further demonstrate that, as early as 3 months after onset of treatment, patients treated with the D2R agonist cabergoline experience an increase in energy expenditure that persists for one year, leading to total body weight and fat loss through a prolactin-independent mechanism. Our results may provide a mechanistic explanation for how clinically used D2R agonists act in the CNS to regulate energy balance.
Collapse
Affiliation(s)
- Cintia Folgueira
- Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo. Hospitalario Universitario de Santiago (CHUS/SERGAS), Instituto de Investigación Sanitaria, Santiago de Compostela, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Daniel Beiroa
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Begoña Porteiro
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Manon Duquenne
- Jean-Pierre Aubert Research Center (JPArc), Laboratory of Development and Plasticity of the Neuroendocrine Brain, Inserm UMR-S 1172, Lille, France
| | | | - Marcos F Fondevila
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Silvia Barja-Fernández
- Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo. Hospitalario Universitario de Santiago (CHUS/SERGAS), Instituto de Investigación Sanitaria, Santiago de Compostela, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Rosalia Gallego
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela, S. Francisco s/n, 15782 Santiago de Compostela (A Coruña), Spain
| | - René Hernández-Bautista
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
| | - Cecilia Castelao
- Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo. Hospitalario Universitario de Santiago (CHUS/SERGAS), Instituto de Investigación Sanitaria, Santiago de Compostela, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Ana Senra
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
| | - Patricia Seoane
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Noemi Gómez
- Molecular Imaging Group, Department of Psychiatry, Radiology and Public Health, Faculty of Medicine Universidade de Santiago de Compostela (USC), Santiago de Compostela 15782 Spain; Molecular Imaging Group. Health Research Institute of Santiago de Compostela (IDIS). Travesía da Choupana s/n Santiago de Compostela. Zip Code: 15706. Spain; Nuclear Medicine Department University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), Travesía Choupana s/n. Santiago de Compostela 15706 Spain
| | - Pablo Aguiar
- Molecular Imaging Group, Department of Psychiatry, Radiology and Public Health, Faculty of Medicine Universidade de Santiago de Compostela (USC), Santiago de Compostela 15782 Spain; Molecular Imaging Group. Health Research Institute of Santiago de Compostela (IDIS). Travesía da Choupana s/n Santiago de Compostela. Zip Code: 15706. Spain; Nuclear Medicine Department University Clinical Hospital Santiago de Compostela (SERGAS) (CHUS), Travesía Choupana s/n. Santiago de Compostela 15706 Spain
| | - Diana Guallar
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
| | - Miguel Fidalgo
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
| | - Amparo Romero-Pico
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Roger Adan
- Brain Center Rudolf Magnus, Department of Neuroscience and Pharmacology, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands
| | - Clemence Blouet
- MRC Metabolic Disease Unit. Institute of Metabolic Science. University of Cambridge, UK
| | - Jose Luís Labandeira-García
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- Networking Research Center on Neurodegenerative Diseases, CIBERNED, Madrid, Spain
| | - Françoise Jeanrenaud
- Laboratory of Metabolism, Division of Endocrinology, Diabetology and Nutrition, Department of Internal Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Imre Kallo
- Laboratory of Endocrine Neurobiology, Institute of Experimental Medicine, HAS, 1083, Budapest, Hungary
| | - Zsolt Liposits
- Laboratory of Endocrine Neurobiology, Institute of Experimental Medicine, HAS, 1083, Budapest, Hungary
| | - Javier Salvador
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
- Department of Endocrinology & Nutrition, Clínica Universidad de Navarra & IdiSNA, Pamplona, Spain
| | - Vincent Prevot
- Jean-Pierre Aubert Research Center (JPArc), Laboratory of Development and Plasticity of the Neuroendocrine Brain, Inserm UMR-S 1172, Lille, France
| | - Carlos Dieguez
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Miguel Lopez
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Emmanuel Valjent
- IGF, Inserm, CNRS, Univ. Montpellier, F-34094 Montpellier, France
| | - Gema Frühbeck
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
- Department of Endocrinology & Nutrition, Clínica Universidad de Navarra & IdiSNA, Pamplona, Spain
| | - Luisa M Seoane
- Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo. Hospitalario Universitario de Santiago (CHUS/SERGAS), Instituto de Investigación Sanitaria, Santiago de Compostela, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Ruben Nogueiras
- CIMUS, Universidade de Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| |
Collapse
|
6
|
Aparicio J, Virgili A, Capdevila J, Muñoz Boza F, Álvarez R, Bosch C, Cámara J, Fernandez-Martos C, Fernandez-Plana J, Gallego J, Gallego R, Hernández-Yagüe X, Macías Declara I, Rodríguez-Salas N, Vera R, Taberner M, Maurel J. Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Carroll EL, Gallego R, Sewell MA, Zeldis J, Ranjard L, Ross HA, Tooman LK, O'Rorke R, Newcomb RD, Constantine R. Multi-locus DNA metabarcoding of zooplankton communities and scat reveal trophic interactions of a generalist predator. Sci Rep 2019; 9:281. [PMID: 30670720 PMCID: PMC6342929 DOI: 10.1038/s41598-018-36478-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Accepted: 11/22/2018] [Indexed: 01/26/2023] Open
Abstract
To understand the ecosystem dynamics that underpin the year-round presence of a large generalist consumer, the Bryde's whale (Balaenoptera edeni brydei), we use a DNA metabarcoding approach and systematic zooplankton surveys to investigate seasonal and regional changes in zooplankton communities and if whale diet reflects such changes. Twenty-four zooplankton community samples were collected from three regions throughout the Hauraki Gulf, New Zealand, over two temperature regimes (warm and cool seasons), as well as 20 samples of opportunistically collected Bryde's whale scat. Multi-locus DNA barcode libraries were constructed from 18S and COI gene fragments, representing a trade-off between identification and resolution of metazoan taxa. Zooplankton community OTU occurrence and relative read abundance showed regional and seasonal differences based on permutational analyses of variance in both DNA barcodes, with significant changes in biodiversity indices linked to season in COI only. In contrast, we did not find evidence that Bryde's whale diet shows seasonal or regional trends, but instead indicated clear prey preferences for krill-like crustaceans, copepods, salps and ray-finned fishes independent of prey availability. The year-round presence of Bryde's whales in the Hauraki Gulf is likely associated with the patterns of distribution and abundance of these key prey items.
Collapse
Affiliation(s)
- E L Carroll
- School of Biological Sciences, University of Auckland, Auckland, New Zealand.
| | - R Gallego
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - M A Sewell
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - J Zeldis
- National Institute of Water and Atmospheric Research, Christchurch, New Zealand
| | - L Ranjard
- Research School of Biology, the Australian National University, Canberra, ACT, Australia
| | - H A Ross
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - L K Tooman
- The Institute for Plant & Food Research, Auckland, New Zealand
| | - R O'Rorke
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
| | - R D Newcomb
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
- The Institute for Plant & Food Research, Auckland, New Zealand
| | - R Constantine
- School of Biological Sciences, University of Auckland, Auckland, New Zealand
- Institute of Marine Science, University of Auckland, Auckland, New Zealand
| |
Collapse
|
8
|
Perarnau-Llobet M, Wilming H, Riera A, Gallego R, Eisert J. Strong Coupling Corrections in Quantum Thermodynamics. Phys Rev Lett 2018; 120:120602. [PMID: 29694098 DOI: 10.1103/physrevlett.120.120602] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Revised: 12/19/2017] [Indexed: 06/08/2023]
Abstract
Quantum systems strongly coupled to many-body systems equilibrate to the reduced state of a global thermal state, deviating from the local thermal state of the system as it occurs in the weak-coupling limit. Taking this insight as a starting point, we study the thermodynamics of systems strongly coupled to thermal baths. First, we provide strong-coupling corrections to the second law applicable to general systems in three of its different readings: As a statement of maximal extractable work, on heat dissipation, and bound to the Carnot efficiency. These corrections become relevant for small quantum systems and vanish in first order in the interaction strength. We then move to the question of power of heat engines, obtaining a bound on the power enhancement due to strong coupling. Our results are exemplified on the paradigmatic non-Markovian quantum Brownian motion.
Collapse
Affiliation(s)
- M Perarnau-Llobet
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany
- ICFO-Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology, 08860 Castelldefels, Barcelona, Spain
| | - H Wilming
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| | - A Riera
- Max-Planck-Institut für Quantenoptik, D-85748 Garching, Germany
- ICFO-Institut de Ciencies Fotoniques, The Barcelona Institute of Science and Technology, 08860 Castelldefels, Barcelona, Spain
| | - R Gallego
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| | - J Eisert
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| |
Collapse
|
9
|
Abstract
We investigate the limitations that emerge in thermodynamic tasks as a result of having local control only over the components of a thermal machine. These limitations are particularly relevant for devices composed of interacting many-body systems. Specifically, we study protocols of work extraction that employ a many-body system as a working medium whose evolution can be driven by tuning the on-site Hamiltonian terms. This provides a restricted set of thermodynamic operations, giving rise to alternative bounds for the performance of engines. Our findings show that those limitations in control render it, in general, impossible to reach Carnot efficiency; in its extreme ramification it can even forbid to reach a finite efficiency or finite work per particle. We focus on the one-dimensional Ising model in the thermodynamic limit as a case study. We show that in the limit of strong interactions the ferromagnetic case becomes useless for work extraction, while the antiferromagnetic case improves its performance with the strength of the couplings, reaching Carnot in the limit of arbitrary strong interactions. Our results provide a promising connection between the study of quantum control and thermodynamics and introduce a more realistic set of physical operations well suited to capture current experimental scenarios.
Collapse
Affiliation(s)
- J Lekscha
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany.,Potsdam Institute for Climate Impact Research, 14473 Potsdam, Germany.,Department of Physics, Humboldt-Universität zu Berlin, 12489 Berlin, Germany
| | - H Wilming
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| | - J Eisert
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| | - R Gallego
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| |
Collapse
|
10
|
Porteiro B, Fondevila MF, Buque X, Gonzalez-Rellan MJ, Fernandez U, Mora A, Beiroa D, Senra A, Gallego R, Fernø J, López M, Sabio G, Dieguez C, Aspichueta P, Nogueiras R. Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis. Mol Metab 2017; 8:132-143. [PMID: 29290620 PMCID: PMC5985045 DOI: 10.1016/j.molmet.2017.12.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 12/12/2017] [Indexed: 12/12/2022] Open
Abstract
Objective Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Methods We used long-term pharmacological activation of p53 by i.p. or oral administration of low-dose doxorubicin in different animal models of NAFLD (high fat diet containing 45% and 60% kcal fat) and NASH (methionine- and choline-deficient diet and choline deficiency combined with high fat diet). We also administered doxorubicin in mice lacking p53 in the liver and in two human hepatic cells lines (HepG2 and THLE2). Results The attenuation of liver damage was accompanied by the stimulation of fatty acid oxidation and decrease of lipogenesis, inflammation, and ER stress. The effects of doxorubicin were abrogated in mice with liver-specific ablation of p53. Finally, the effects of doxorubicin on lipid metabolism found in animal models were also present in two human hepatic cells lines, in which the drug stimulated fatty acid oxidation and inhibited de novo lipogenesis at doses that did not cause changes in apoptosis or cell viability. Conclusion These data provide new evidence for targeting p53 as a strategy to treat liver disease. Intraperitoneal and oral low-dose doxorubicin ameliorates NAFLD and NASH in animal models. Doxorubicin requires p53 for its hepatic actions. Doxorubin decreases lipid content in human hepatocytes without affecting cell viability and apoptosis.
Collapse
Affiliation(s)
- Begoña Porteiro
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Marcos F Fondevila
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Xabier Buque
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Spain; Biocruces Research Institute, Spain
| | - Maria J Gonzalez-Rellan
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Uxia Fernandez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Alfonso Mora
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - Daniel Beiroa
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Ana Senra
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
| | - Rosalia Gallego
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain
| | - Johan Fernø
- KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway; Hormone Laboratory, Haukeland University Hospital, Bergen, Norway
| | - Miguel López
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Guadalupe Sabio
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain
| | - Carlos Dieguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Patricia Aspichueta
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Spain; Biocruces Research Institute, Spain
| | - Rubén Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain.
| |
Collapse
|
11
|
Santos-Zas I, Negroni E, Mamchaoui K, Mosteiro CS, Gallego R, Butler-Browne GS, Pazos Y, Mouly V, Camiña JP. Obestatin Increases the Regenerative Capacity of Human Myoblasts Transplanted Intramuscularly in an Immunodeficient Mouse Model. Mol Ther 2017; 25:2345-2359. [PMID: 28750736 DOI: 10.1016/j.ymthe.2017.06.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Revised: 06/23/2017] [Accepted: 06/24/2017] [Indexed: 02/08/2023] Open
Abstract
Although cell-based therapy is considered a promising method aiming at treating different muscular disorders, little clinical benefit has been reported. One of major hurdles limiting the efficiency of myoblast transfer therapy is the poor survival of the transplanted cells. Any intervention upon the donor cells focused on enhancing in vivo survival, proliferation, and expansion is essential to improve the effectiveness of such therapies in regenerative medicine. In the present work, we investigated the potential role of obestatin, an autocrine peptide factor regulating skeletal muscle growth and repair, to improve the outcome of myoblast-based therapy by xenotransplanting primary human myoblasts into immunodeficient mice. The data proved that short in vivo obestatin treatment of primary human myoblasts not only enhances the efficiency of engraftment, but also facilitates an even distribution of myoblasts in the host muscle. Moreover, this treatment leads to a hypertrophic response of the human-derived regenerating myofibers. Taken together, the activation of the obestatin/GPR39 pathway resulted in an overall improvement of the efficacy of cell engraftment within the host's skeletal muscle. These data suggest considerable potential for future therapeutic applications and highlight the importance of combinatorial therapies.
Collapse
Affiliation(s)
- Icia Santos-Zas
- Laboratorio de Endocrinología Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), 15706 Santiago de Compostela, Spain
| | - Elisa Negroni
- Sorbonne Universités, Université Pierre et Marie Curie Université Paris 06, INSERM UMRS974, Center for Research in Myology, 47 Boulevard de l'hôpital, 75013 Paris, France
| | - Kamel Mamchaoui
- Sorbonne Universités, Université Pierre et Marie Curie Université Paris 06, INSERM UMRS974, Center for Research in Myology, 47 Boulevard de l'hôpital, 75013 Paris, France
| | - Carlos S Mosteiro
- Laboratorio de Endocrinología Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), 15706 Santiago de Compostela, Spain
| | - Rosalia Gallego
- Departamento de Ciencias Morfológicas, Universidad de Santiago de Compostela, 15704 Santiago de Compostela, Spain
| | - Gillian S Butler-Browne
- Sorbonne Universités, Université Pierre et Marie Curie Université Paris 06, INSERM UMRS974, Center for Research in Myology, 47 Boulevard de l'hôpital, 75013 Paris, France
| | - Yolanda Pazos
- Laboratorio de Patología Digestiva, IDIS, CHUS, SERGAS, 15706 Santiago de Compostela, Spain
| | - Vincent Mouly
- Sorbonne Universités, Université Pierre et Marie Curie Université Paris 06, INSERM UMRS974, Center for Research in Myology, 47 Boulevard de l'hôpital, 75013 Paris, France.
| | - Jesus P Camiña
- Laboratorio de Endocrinología Celular, Instituto de Investigación Sanitaria de Santiago (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Servicio Gallego de Salud (SERGAS), 15706 Santiago de Compostela, Spain.
| |
Collapse
|
12
|
Imbernon M, Sanchez‐Rebordelo E, Romero‐Picó A, Kalló I, Chee MJ, Porteiro B, Al‐Massadi O, Contreras C, Fernø J, Senra A, Gallego R, Folgueira C, Seoane LM, van Gestel M, Adan RA, Liposits Z, Dieguez C, López M, Nogueiras R. Hypothalamic kappa opioid receptor mediates both diet-induced and melanin concentrating hormone-induced liver damage through inflammation and endoplasmic reticulum stress. Hepatology 2016; 64:1086-104. [PMID: 27387967 PMCID: PMC5129461 DOI: 10.1002/hep.28716] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 07/05/2016] [Indexed: 12/14/2022]
Abstract
UNLABELLED The opioid system is widely known to modulate the brain reward system and thus affect the behavior of humans and other animals, including feeding. We hypothesized that the hypothalamic opioid system might also control energy metabolism in peripheral tissues. Mice lacking the kappa opioid receptor (κOR) and adenoviral vectors overexpressing or silencing κOR were stereotaxically delivered in the lateral hypothalamic area (LHA) of rats. Vagal denervation was performed to assess its effect on liver metabolism. Endoplasmic reticulum (ER) stress was inhibited by pharmacological (tauroursodeoxycholic acid) and genetic (overexpression of the chaperone glucose-regulated protein 78 kDa) approaches. The peripheral effects on lipid metabolism were assessed by histological techniques and western blot. We show that in the LHA κOR directly controls hepatic lipid metabolism through the parasympathetic nervous system, independent of changes in food intake and body weight. κOR colocalizes with melanin concentrating hormone receptor 1 (MCH-R1) in the LHA, and genetic disruption of κOR reduced melanin concentrating hormone-induced liver steatosis. The functional relevance of these findings was given by the fact that silencing of κOR in the LHA attenuated both methionine choline-deficient, diet-induced and choline-deficient, high-fat diet-induced ER stress, inflammation, steatohepatitis, and fibrosis, whereas overexpression of κOR in this area promoted liver steatosis. Overexpression of glucose-regulated protein 78 kDa in the liver abolished hypothalamic κOR-induced steatosis by reducing hepatic ER stress. CONCLUSIONS This study reveals a novel hypothalamic-parasympathetic circuit modulating hepatic function through inflammation and ER stress independent of changes in food intake or body weight; these findings might have implications for the clinical use of opioid receptor antagonists. (Hepatology 2016;64:1086-1104).
Collapse
Affiliation(s)
- Monica Imbernon
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Estrella Sanchez‐Rebordelo
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Amparo Romero‐Picó
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Imre Kalló
- Laboratory of Endocrine NeurobiologyInstitute of Experimental Medicine, Hungarian Academy of SciencesBudapestHungary
| | - Melissa J. Chee
- Division of Endocrinology, Department of MedicineBeth Israel Deaconess Medical Center, Harvard Medical SchoolBostonMA
| | - Begoña Porteiro
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Omar Al‐Massadi
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Cristina Contreras
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Johan Fernø
- Department of Clinical ScienceKG Jebsen Center for Diabetes Research, University of BergenBergenNorway
| | - Ana Senra
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Rosalia Gallego
- Department of Morphological Sciences, School of MedicineUniversity of Santiago de Compostela‐Instituto de Investigación Sanitaria
| | - Cintia Folgueira
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain,Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo, Hospitalario Universitario de Santiago (CHUS/SERGAS)Santiago de CompostelaSpain
| | - Luisa M. Seoane
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain,Grupo Fisiopatología Endocrina, Instituto de Investigación Sanitaria de Santiago de Compostela, Complexo, Hospitalario Universitario de Santiago (CHUS/SERGAS)Santiago de CompostelaSpain
| | - Margriet van Gestel
- Department of Neuroscience and PharmacologyRudolf Magnus Institute of Neuroscience, University Medical Center UtrechtUtrechtThe Netherlands
| | - Roger A. Adan
- Department of Neuroscience and PharmacologyRudolf Magnus Institute of Neuroscience, University Medical Center UtrechtUtrechtThe Netherlands
| | - Zsolt Liposits
- Laboratory of Endocrine NeurobiologyInstitute of Experimental Medicine, Hungarian Academy of SciencesBudapestHungary
| | - Carlos Dieguez
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Miguel López
- Department of PhysiologyCIMUS, University of Santiago de Compostela‐Instituto de Investigación Sanitaria,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn)Santiago de CompostelaSpain
| | - Ruben Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria. .,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela, Spain.
| |
Collapse
|
13
|
Abstract
The second law of thermodynamics, formulated as an ultimate bound on the maximum extractable work, has been rigorously derived in multiple scenarios. However, the unavoidable limitations that emerge due to the lack of control on small systems are often disregarded when deriving such bounds, which is specifically important in the context of quantum thermodynamics. Here we study the maximum extractable work with limited control over the working system and its interaction with the heat bath. We derive a general second law when the set of accessible Hamiltonians of the working system is arbitrarily restricted. We then apply our bound to particular scenarios that are important in realistic implementations: limitations on the maximum energy gap and local control over many-body systems. We hence demonstrate in what precise way the lack of control affects the second law. In particular, contrary to the unrestricted case, we show that the optimal work extraction is not achieved by simple thermal contacts. Our results not only generalize the second law to scenarios of practical relevance, but also take first steps in the direction of local thermodynamics.
Collapse
Affiliation(s)
- H Wilming
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| | - R Gallego
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| | - J Eisert
- Dahlem Center for Complex Quantum Systems, Freie Universität Berlin, 14195 Berlin, Germany
| |
Collapse
|
14
|
Gallego R, Flores A. Management And Psychiatric Manifestations Of Anti-NMDA Receptor Encephalitis, A Case Report. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.1946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
IntroductionAnti-NMDA receptor (NMDAR) encephalitis, formally recognized in 2007 by Dalmau et al, is an autoimmune disorder with a complex presentation that includes psychiatric symptoms, memory deficits, and autonomic instability. The exact incidence is unknown but age, gender, and ethnicity may all play a role. Presence of antibodies against the GluN1 subunit of the NMDAR in the CSF and serum confirm the diagnosis of NMDAR encephalitis.Case reportWe report the case of a previously healthy, 19-year-old woman, 6 weeks pregnant. She had a generalized tonic-clonic seizure followed by psychiatric symptoms, including insomnia, emotional lability, delusions, and disorganized behavior. During the course of the disease, she demonstrated speech impairments and catatonic features associated with abnormal movements.She was provided lorazepam 1 mg twice a day to treat her catatonic symptoms, her insomnia and her speech improved. Olanzapine was introduced, reaching a dose of 20 mg/day for managing psychosis and agitation.DiscussionNMDA-R encephalitis is a novel disorder with prominent psychiatric manifestations that is widely underdiagnosed. Neuroleptics may be helpful for managing psychosis and agitation, but may exacerbate movement abnormalities. Benzodiazepines are helpful for agitation, insomnia and catatonia associated with this condition.ConclusionEarlier recognition of this illness is crucial as prompt diagnosis and multidisciplinary treatment, can potentially improve prognosis. There is an increasing need for psychiatrists to become aware of the disorder and consider it in their differential diagnosis, specially in patients with new onset psychosis, history of encephalitis or subtle neurological symptoms. Careful selection of psychopharmacological interventions may reduce suffering.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
15
|
Duarte L, Ruão M, Gallego R. Focal choroidal changes on diabetic macular edema. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- L. Duarte
- Ophthalmology; Centro Hospitalar Entre o Douro e Vouga; Santa Maria da Feira Portugal
| | - M. Ruão
- Ophthalmology; Centro Hospitalar Entre o Douro e Vouga; Santa Maria da Feira Portugal
| | - R. Gallego
- Unidad de Macula; Hospital Universitario y Politécnico La Fe; Valencia Spain
| |
Collapse
|
16
|
Gallego R, Arteaga J, Valencia C, Franco J. Thickening properties of several NCO-functionalized cellulose derivatives in castor oil. Chem Eng Sci 2015. [DOI: 10.1016/j.ces.2015.05.007] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs 2014; 31:1573-9. [PMID: 24077981 DOI: 10.1007/s10637-013-0020-2] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Accepted: 08/23/2013] [Indexed: 02/06/2023]
Abstract
BACKGROUND Cisplatin and fluoropyrimidine (CF) are standard first- line treatment in advanced gastric cancer, but no second-line treatment has yet been established. We present a phase II study in which we evaluated the efficacy and toxicity of the combination of Sorafenib (S), and Oxaliplatin as second-line therapy. METHODS Patients with progressive gastric adenocarcinoma after CF- first-line, ECOG 0-2, and measurable disease were included. The primary objective was PFS. Treatment doses were Oxaliplatin 130 mg/m²/3 weeks and Sorafenib 800 mg/bid/d. RESULTS We included 40 patients. CR was 2.5% and SD was 47.2%. Grade 3-4 toxic effects were neutropenia (9.8%), thrombocytopenia (7.3%), neurotoxicity (4.9%) and diarrhea (4.9%). Median PFS was 3 months (95%CI: 2.3-4.1) and median OS was 6.5 months (95% CI: 5.2-9.6). Time to progression (TTP) to first line therapy was a prognosis factor. Median OS was 9.7 months when time-to-progression during first-line chemotherapy was >6 months and 5.6 m when it was <6 months (p = 0.04). CONCLUSIONS Time-to-progression under a CF-based first-line therapy determines subgroups of GC patients with different prognosis. The combination of Oxaliplatin-Sorafenib in advanced GC patients previously treated with CF appears safe, but our results do not support the implementation of a phase III trial.
Collapse
|
18
|
Beltrán-Catalán E, Calvo-Río V, Blanco-Alonso R, Ortego Centeno N, García Serrano J, Martinez-Costa Pérez L, Fonollosa Calduch A, Hernandez Garfella M, Valls E, Francisco Hernández F, Reyes M, Torre I, Maíz O, Blanco A, Muñoz-Fernández S, Esteban M, Pato-Cour E, Diaz M, Gallego R, Cordero-Coma M, Ortiz F, Cañal J, González-Gay M. AB0571 High Dose Intravenous Methylprednisolone Induces RAPID Improvement in Severe Ocular Inflammation. Multicenter Study of 104 Cases. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
19
|
Imbernon M, Sanchez-Rebordelo E, Gallego R, Gandara M, Lear P, Lopez M, Dieguez C, Nogueiras R. Hypothalamic KLF4 mediates leptin's effects on food intake via AgRP. Mol Metab 2014; 3:441-51. [PMID: 24944903 PMCID: PMC4060210 DOI: 10.1016/j.molmet.2014.04.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 04/01/2014] [Accepted: 04/02/2014] [Indexed: 11/18/2022] Open
Abstract
Krüppel-like factor 4 (KLF4) is a zinc-finger-type transcription factor expressed in a range of tissues that plays multiple functions. We report that hypothalamic KLF4 represents a new transcription factor specifically modulating agouti-related protein (AgRP) expression in vivo. Hypothalamic KLF4 colocalizes with AgRP neurons and is modulated by nutritional status and leptin. Over-expression of KLF4 in the hypothalamic arcuate nucleus (ARC) induces food intake and increases body weight through the specific stimulation of AgRP, as well as blunting leptin sensitivity in lean rats independent of forkhead box protein 01 (FoxO1). Down-regulation of KLF4 in the ARC inhibits fasting-induced food intake in both lean and diet-induced obese (DIO) rats. Silencing KLF4, however, does not, on its own, enhance peripheral leptin sensitivity in DIO rats.
Collapse
Affiliation(s)
- Monica Imbernon
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Estrella Sanchez-Rebordelo
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Rosalia Gallego
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
| | - Marina Gandara
- Department of Morphological Sciences, School of Medicine, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
| | - Pamela Lear
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
| | - Miguel Lopez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
| | - Carlos Dieguez
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
- Corresponding authors. Department of Physiology, Centro de Investigaciones Medicas de la Universidad de Santiago (CIMUS), University of Santiago de Compostela & CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Avenida de Barcelona s/n, 15782 Santiago de Compostela, A Coruña, Spain. Tel.: +34 881815437.
| | - Ruben Nogueiras
- Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), 15706, Spain
- Corresponding authors. Department of Physiology, Centro de Investigaciones Medicas de la Universidad de Santiago (CIMUS), University of Santiago de Compostela & CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Avenida de Barcelona s/n, 15782 Santiago de Compostela, A Coruña, Spain. Tel.: +34 881815437.
| |
Collapse
|
20
|
Gallego R, Arteaga J, Valencia C, Franco J. Rheology and thermal degradation of isocyanate-functionalized methyl cellulose-based oleogels. Carbohydr Polym 2013; 98:152-60. [DOI: 10.1016/j.carbpol.2013.04.104] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2013] [Revised: 04/22/2013] [Accepted: 04/29/2013] [Indexed: 10/26/2022]
|
21
|
Gallego R, López-Quintana S, Basurto F, Núñez K, Villarreal N, Merino J. Synthesis of new compatibilizers to poly(lactic acid) blends. POLYM ENG SCI 2013. [DOI: 10.1002/pen.23589] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- R. Gallego
- Department of Materials-Process-Product Foundation for Research and Development in Transport and Energy (CIDAUT); Parque Tecnológico de Boecillo; 47151, Boecillo Valladolid Spain
| | - S. López-Quintana
- Materials area Miranda de Ebro's Technology Center (CTME); 09200, Miranda de Ebro Burgos Spain
| | - F. Basurto
- Departament of Condensed Matter Physics; Escuela de Ingenierías Industriales; University of Valladolid; Paseo del Cauce, 59 47011 Valladolid Spain
| | - K. Núñez
- Departament of Condensed Matter Physics; Escuela de Ingenierías Industriales; University of Valladolid; Paseo del Cauce, 59 47011 Valladolid Spain
| | - N. Villarreal
- Department of Materials-Process-Product Foundation for Research and Development in Transport and Energy (CIDAUT); Parque Tecnológico de Boecillo; 47151, Boecillo Valladolid Spain
| | - J.C. Merino
- Department of Materials-Process-Product Foundation for Research and Development in Transport and Energy (CIDAUT); Parque Tecnológico de Boecillo; 47151, Boecillo Valladolid Spain
- Departament of Condensed Matter Physics; Escuela de Ingenierías Industriales; University of Valladolid; Paseo del Cauce, 59 47011 Valladolid Spain
| |
Collapse
|
22
|
Raghay K, Gallego R, Scoazec JY, Garcia-Caballero T, Morel G. Different ghrelin localisation in adult human and rat endocrine pancreas. Cell Tissue Res 2013; 352:487-94. [PMID: 23584608 DOI: 10.1007/s00441-013-1593-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2012] [Accepted: 02/15/2013] [Indexed: 12/25/2022]
Abstract
Ghrelin is an endocrine peptide that has been identified in gastric oxyntic glands and that induces growth hormone secretion in the pituitary gland. This growth hormone secretagogue is expressed in many tissues such as stomach, pituitary gland, thyroid, testis, placenta and pancreas. Initial studies of ghrelin focused on its role as a circulating orexigenic signal. However, ghrelin has also been found to be involved in the modulation of glucose homeostasis. Although a number of studies have reported ghrelin expression in developing pancreas, the location of ghrelin-immunoreactive cells in adult pancreas (epsilon cells) remains controversial. In this study, we have analysed the distribution of pancreatic epsilon cells in adult human and rat islets by immunohistochemistry and in situ hybridisation. In humans, our immunohistochemical analysis has shown that ghrelin is expressed in glucagon-secreting cells, whereas in rats, it is present in insulin-secreting cells. Similar observations have been revealed by in situ hybridisation.
Collapse
Affiliation(s)
- Kawtar Raghay
- Inserm U 1052/CNRS UMR 5286, Claude Bernard University, Lyon, France
| | | | | | | | | |
Collapse
|
23
|
Pera M, Gallego R, Montagut C, Martín-Richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, Bellmunt J, Maurel J. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol 2012; 23:664-670. [PMID: 21652581 DOI: 10.1093/annonc/mdr291] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Based on a phase I study showing the feasibility of combining of oxaliplatin, cisplatin, and 5-fluorouracil (5-FU) (OCF) with radiation therapy (RT) in esophageal cancer, the efficacy of this regimen in esophageal, gastroesophageal (GE), and gastric (G) cancer was assessed in this phase II multicenter study. PATIENTS AND METHODS Patients with resectable tumors were eligible. Treatment included two cycles of oxaliplatin 85 mg/m(2), cisplatin 55 mg/m(2), and continuously infused 5-FU 3 g/m(2) in 96 h and concurrent RT (45 Gy), followed by surgery after 6-8 weeks. Primary end point was complete pathologic response (pCR). RESULTS Forty-one patients were enrolled. Tumor location was esophagus 39% (squamous 10/adenocarcinoma 6), GE junction 32%, and stomach 29%. G3-G4 adverse events included asthenia (27%) and neutropenia (14%). One toxic death occurred. Thirty-one patients (75.6%) underwent surgery (R0 in 94%). Pathologic response was achieved in 58% of patients, with pCR in 50% and 16% of esophageal and GE/G cancer, respectively. pCR was achieved in 67% of squamous cell carcinoma. Survival: median follow-up, 50.4 months; median progression-free survival and overall survival were 23.2 and 28.4 months, respectively. CONCLUSION Preoperative OCF plus RT showed an acceptable toxicity and promising activity especially in squamous cell esophageal cancer.
Collapse
Affiliation(s)
- M Pera
- Section of Gastrointestinal Surgery, Hospital Universitario del Mar and Institut de Recerca Hospital del Mar (IMIM), Universitat Autónoma de Barcelona, Barcelona.
| | - R Gallego
- Department of Medical Oncology and Radiation Therapy, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona Medical School, Barcelona
| | - C Montagut
- Service of Medical Oncology, Hospital Universitario del Mar and Institut de Recerca Hospital del Mar (IMIM), Barcelona
| | | | | | - C Conill
- Department of Medical Oncology and Radiation Therapy, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona Medical School, Barcelona
| | - A Reig
- Services of Radiotherapy, Hospital Universitario del Mar and Institut de Recerca Hospital del Mar (IMIM), Barcelona
| | | | - L Pétriz
- Services of Radiation Therapy, Hospital de Sant Pau, Barcelona
| | - D Momblan
- Service of Gastrointestinal Surgery, Hospital Clinic, Barcelona, Spain
| | - J Bellmunt
- Service of Medical Oncology, Hospital Universitario del Mar and Institut de Recerca Hospital del Mar (IMIM), Barcelona
| | - J Maurel
- Department of Medical Oncology and Radiation Therapy, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona Medical School, Barcelona
| |
Collapse
|
24
|
Tabernero J, Tabernero J, Elez M, Capdevila J, Macarulla T, Gallego R. 400 INVITED Strategies of Prolonged Multimodal Treatment on Metastatic Colorectal Carcinoma (mCRC): Maintenance Treatment With Targeted Agents. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70615-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
25
|
Argiles G, Castillo O, Navalpotro B, Espin E, Moreno-Fernandez D, Macarulla T, Fernandez MEE, Alsina M, Gallego R, Sánchez-Ollé G, Giralt J, Tabernero J, Capdevila J. Perioperative treatment for locally advanced rectal carcinoma (LARC) in elderly patients: Evaluation of compliance, tolerability, and outcome in a Spanish referral institution. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Ben-Batalla I, Seoane S, Garcia-Caballero T, Gallego R, Macia M, Gonzalez LO, Vizoso F, Perez-Fernandez R. Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. J Clin Invest 2010; 120:4289-302. [PMID: 21060149 DOI: 10.1172/jci42015] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2010] [Accepted: 09/15/2010] [Indexed: 12/28/2022] Open
Abstract
The Pit-1 transcription factor (also know as POU1F1) plays a critical role in cell differentiation during organogenesis of the anterior pituitary in mammals and is a transcriptional activator for pituitary gene transcription. Increased expression of Pit-1 has been reported in human tumorigenic breast cells. Here, we found that Pit-1 overexpression or knockdown in human breast cancer cell lines induced profound phenotypic changes in the expression of proteins involved in cell proliferation, apoptosis, and invasion. Some of these protumorigenic effects of Pit-1 were mediated by upregulation of Snai1, an inductor of the epithelial-mesenchymal transition. In immunodeficient mice, Pit-1 overexpression induced tumoral growth and promoted metastasis in lung. In patients with invasive ductal carcinoma of the breast and node-positive tumor, high expression of Pit-1 was significantly correlated with Snai1 positivity. Notably, in these patients elevated expression of Pit-1 was significantly and independently associated with the occurrence of distant metastasis. These findings suggest that Pit-1 could help to make a more accurate prognosis in patients with node-positive breast cancer and may represent a new therapeutic target.
Collapse
Affiliation(s)
- Isabel Ben-Batalla
- Department of Physiology, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Carrera G, Garcia-Albeniz X, Alonso-Espinaco V, Pericay C, Alonso V, Escudero MP, Fernandez-Martos C, Gallego R, Castellvi-Bel S, Maurel J. MMP-7 serum levels as predictor or prognostic of cetuximab benefit in the treatment of advanced colorectal cancer: Results from a HCB-05 prospective trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Cobo M, Ferrer N, Paredes A, Mendez M, Muñoz-Langa J, Rueda A, Alvarez De Mon M, Sanchez-Hernandez A, Gallego R, Torrego J. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC): Final report. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Pineda E, Garcia-Albeniz X, Delgado S, Conill C, Gines A, Ayuso J, Gallego R, Cuatrecasas M, Lacy A, Maurel J. Preoperative chemoradiotherapy (QRTP) and total mesorectal excision (TME) by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Gallego R, Henriquez F, Oliva E, Camacho R, Hernández R, Hortal L, Sablón N, Quintana B, Santana R, Gonzalez F, Palop L, Vega N. Switching to sirolimus in renal transplant recipients with hepatitis C virus: a safe option. Transplant Proc 2010; 41:2334-6. [PMID: 19715912 DOI: 10.1016/j.transproceed.2009.06.064] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION The presence of hepatitis C virus (HCV) in renal transplant recipients is an independent risk factor for death and graft failure. Chronic allograft nephropathy (CAN) favored by the use of calcineurin inhibitors (CNI) is one of the main causes of graft loss, whereas sirolimus (SRL) has proven to maintain better graft function with lower rates of CAN. OBJECTIVES AND METHODS We developed a protocol to evaluate the safety of SRL in transplant recipients with respect to HCV. We studied 5 patients (3 men) of mean age 52 +/- 9.2 years with HCV who had not received antiviral treatment. The viral genotypes were 1b in 4 cases and 2a/2c in 1 case. Basic immunosuppression was mycophenolate mofetil (MMF) and corticosteroids in all patients, cyclosporine (CsA) in 4 cases, and tacrolimus (Tac) in 1 case. Before the switch, a renal biopsy was performed and viral replication and cryoglobulins determined. RESULTS Biopsy provided a diagnosis of CAN in 1 case, CNI toxicity-associated CAN in 2 cases, CNI toxicity in 1 case, and no renal damage in the remaining case. We observed a nonsignificant decrease in the number (log) of viral copies with a stabilization of renal function but with a slight to moderate increase in proteinuria. CONCLUSIONS The switch seemed to be safe with no increase in viral copies. Graft renal function remained stable with increased proteinuria that must be supervised, even though it did not reach statistical significance.
Collapse
Affiliation(s)
- R Gallego
- Nephrology Service, Hospital Universitario of Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Gallego R, García-López D, Merino JC, Pastor JM. The effect of montmorillonite and compatibilizer quantities on stiffness and toughness of polyamide nanoblends. POLYM INT 2009. [DOI: 10.1002/pi.2724] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
33
|
Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, de Mon MÁ, Sánchez-Hernández A, Gallego R, Torrego J. 9149 Phase II study of bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (p) with metastatic non squamous non-small-cell lung cancer (NSCLC). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71862-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
34
|
Horndler C, Gallego R, Alonso V, Alonso V, Escudero P, Jimeno M, Garcia-Albeniz X, Fernandez-Martos C, Castellví-Bel S, Maurel J. Coexpression of matrix metalloproteinase-7 (MMP7) and phosphorylated insulin growth factor receptor I (pIGF-IR) as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4063 Background: IGF-IR is supposed to have anti-apoptotic and mitogenic properties in colorectal cancer and by transactivation can promote EGFR phosphorylation. MMP-7 is produced by colorectal cancer cells and by degrading IGFBP-3 can activate IGF-IR. Methods: We retrospectively investigated the role of pIGF-IR immunoreactivity (IHC) (Rubini) and MMP-7 IHC in primary CRC or metastases, to predict response rate (RR), progression free survival (PFS) and overall survival (OS) in ACRC patients (pts) treated with either cetuximab or panitumumab as second or third line therapy. RAS mutational status of codons 12/13 was determined using quantitative PCR-based assay. CT scans were done every 1.5–2 months (m) until progressive disease. Results: A total of 99 pts with available tissue from 168 pts with ACRC treated with anti-EGFR therapy in 4 Spanish Institutions, were analysed for RAS mutational status, pIGF-1R and MMP-7. There were no major differences in RR (18.8 vs 16%), PFS [3.3 vs. 3.1 months (m)] and OS (7.7 vs. 7m) between the whole and selected cohort. Fifty-seven (57.6%) pts were male, the median age was 62 (range 34–79) years, the median number of previous chemotherapy lines was 2 (range 1–3) and PS was distributed as follow: PS0, 17 (17.2 %) pts; PS1, 66 (66.7%) pts and PS2, 16 (16.2%) pts. Expression of MMP-7 and pIGF-1R were observed in 48 (48.5%) and 52 (52.5%) pts respectively. Co-expression of MMP-7 and pIGF-1R [Double Positive (DP)] was observed in 26 (26.3 %) pts and in 16 (24%) out of 66 RAS wild-type (WTRAS) pts. There was no association between RAS mutational status and DP (p=0.52). DP progressed more than non-DP pts both in the overall sample (73 vs. 43%, p=0.028) and in WTRAS pts (75 vs. 32%, p=0.011). In the subset of WTRAS pts, DP pts also have a poorer OS: 6.4 (95% CI 5.8–7.1) m vs. 8.6 (95%CI 6.0–11.3) m (p=0.005), and a trend for worse PFS 2.7 vs 4.0 m (p=0.11). Conclusions: Co-expression of pIGF-1R and MMP7 is associated with resistance to anti- EGFR therapy in WTRAS pts. Our study suggests that pts with WTRAS and DP could be a target population to assay new anti-IGF-1R compounds. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Horndler
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - R. Gallego
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - V. Alonso
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - V. Alonso
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - P. Escudero
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - M. Jimeno
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - X. Garcia-Albeniz
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - C. Fernandez-Martos
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - S. Castellví-Bel
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| | - J. Maurel
- Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínic Barcelona, Barcelona, Spain; Hospital Clínico Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncologia, Valencia, Spain
| |
Collapse
|
35
|
Gallego R, Fuster D, Ginés A, Ortín J, Ayuso JR, Momblan D, Arguis P, Conill C, Pons F, Maurel J. Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15598 Background: 1) To evaluate the usefulness of Positron Emission Tomography with combined 18F-Fluorodeoxyglucose with Computed Tomography (PET/CT) in the diagnosis of distant metastases in patients with gastric adenocarcinoma (GAC) compared to spiral double contrast thoracoabdominal Computed Tomography (CT); 2) To establish the utility of PET/CT in the detection of peritoneal carcinomatosis compared to laparoscopy. Methods: Thirty prospective patients (22 men, 8 women; mean age 67±11) who underwent endoscopic ultrasound and were classified as T2–3N1 or T3Nx GAC were included in this study. Whole body images were obtained 1 hour after injection of 370 MBq of 18F-Fluorodeoxyglucose. CT was performed within 2 weeks of PET/CT. Laparoscopy was performed without remarkable incidences. All findings were confirmed by histopathology examination and/or by at least 6 months follow- up. Results: Distant metastases were found in 9/30 cases: carcinomatosis (3), retroperitoneal (3) or mediastinal (2) pathological lymph nodes and one case of bone metastases (1). PET/CT diagnosed unsuspected distant metastases by CT in 4/9 patients (retroperitoneal (1) or mediastinal (2) pathological lymph nodes and 1 case of bone metastasis in the spine). In 1/3 patients with histopathological confirmed diagnosis of peritoneal carcinomatosis by laparoscopic findings was negative by PET/CT, and considered as a false negative case. On the other hand, 3 patients with initially positive peritoneal carcinomatosis by invasive laparoscopy were finally diagnosed as benign lesions. These lesions did not show significant uptake in PET/CT and were considered as true negative cases. Conclusions: 1) PET/CT is useful in the diagnosis of distant metastases in patients with GAC 2) Further studies are needed to establish the role of PET/CT to detect peritoneal carcinomatosis. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - A. Ginés
- Hospital Clínic, Barcelona, Spain
| | - J. Ortín
- Hospital Clínic, Barcelona, Spain
| | | | | | | | | | - F. Pons
- Hospital Clínic, Barcelona, Spain
| | | |
Collapse
|
36
|
Pineda E, Pericay C, García-Albéniz X, Augé J, Alonso V, Escudero P, Fernández-Martos C, Gallego R, Maurel J. Serum IGFBP3, IGF-I, and MMP7 changes in advanced colorectal cancer (ACRC) patients (pts) treated with anti-EGFR therapy: A GEMCAD study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15109 Background: Insulin-like growth factor-I (IGF-I) is a potent mitotic and anti-apoptotic peptide, whereas IGF binding protein-3 (IGFBP3) seems to have pro-apoptotic effects. Matrix metalloproteinase-7 (MMP7), an enzyme with in vitro ability to degrade IGFBP3, has been shown to be a prognostic factor in ACRC. Methods: This is a prospective single cohort traslational study. Pts undergoing second/third line with irinotecan plus anti-EGFR therapy were eligible as cases. Patients with ACRC not undergoing therapy were eligible as controls. IGFBP3 and MMP7 were measured in serum with immunoassays at baseline and at 48h after treatment start. KRAS mutation status in codons 12/13 was determined by sequencing in 53 pts. The primary endpoint is to define the IGFBP3 and MMP7 variation under anti-EGFR therapy. IGFBP3 was used as a continuous variable and MMP7 was used to create two groups by its third quartile. Results: Eighty-five cases and 25 controls were recruited. No significant changes at 48h in IGF-I and IGFBP3 were found, but a significant decrease in MMP7 from 10.8 (95%IC 8.3–13.3) to 8.4 ng/ml (95%IC 6–10.9) was observed in cases (p<0.001) in contrast with controls, where no changes were found. Splitting the sample by the third quartile of MMP7 interesting changes in IGFBP3 variations were found. In the group with low levels of MMP7, IGFBP3 increases from 1,859 to 1,959 ng/ml (p=0.043) 48h after treatment initiation; on the contrary, in the group with high levels of MMP7, IGFBP3 decreases from 1,811 to 1,757 ng/ml (p=0.741). We found no association with IGFBP3 and neither response rate, time to progression nor overall survival. This latter analysis was also done only in pts with wild-type KRAS, without any change in the results. Conclusions: In pts with ACRC treated with anti-EGFR therapy, serum levels of IGFBP3 variations depend on basal MMP7 levels. IGFBP3 failed to be a predictive/prognostic factor in our sample although the limited number of KRAS pts analyzed can influence our results. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Pineda
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - C. Pericay
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - X. García-Albéniz
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - J. Augé
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - V. Alonso
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - P. Escudero
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - C. Fernández-Martos
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - R. Gallego
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| | - J. Maurel
- Hospital Clínic, Barcelona, Spain; Hospital Parc Taulí, Sabadell, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Clínico de Zaragoza, Zaragoza, Spain; Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
37
|
Leon L, Vázquez S, Gracia JM, Lázaro M, Fírvida JL, Casal J, Amenedo M, Santomé L, Gallego R, Anido U. Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19089 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel or cisplatin-gemcitabine. This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine. Methods: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression. Main eligibility criteria were: PS 0–1, no brain metastases, no history of hemoptysis, stable cardiac condition and no full dose anticoagulation. Primary endpoint was progression-free survival and secondary endpoints were RR, duration of response, OS, 1-year survival and safety profile of the combination. Results: 38 p have been enrolled in the study and data of 27 p have been included in this analysis. P characteristics were: male 66.7%; median age 57 years (range 41–74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1. Median number of cycles for B/cisplatin/vinorelbine was 4.0 (range 1–6) and median number of cycles for B maintenance was 2 (range 1–4). 17 p were evaluable for response according to RECIST criteria: PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months (range 0.7–11.1), median PFS was 4.6 months (95% CI: 2.6–6.6) and median OS has not been reached yet. Hematological toxicities were: 1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 3/4 non hematological toxicities were: vomiting (1p gr. 4), high blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 respiratory infection. No grade 3/4 hemoptysis were reported. Conclusions: This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC. Survival data will be updated. [Table: see text]
Collapse
Affiliation(s)
- L. Leon
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - S. Vázquez
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. M. Gracia
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Lázaro
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. L. Fírvida
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - J. Casal
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - M. Amenedo
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - L. Santomé
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - R. Gallego
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| | - U. Anido
- Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Complejo Hospitalario Xeral-Calde, Lugo, Spain; Hospital de Cabueñes, Gijón, Spain; C.H. Universitario de Vigo - Hospital Xeral Cíes, Vigo, Spain; Complejo Hospitalario de Ourense, Ourense, Spain; C.H. Universitario de Vigo - Hospital do Meixoeiro, Vigo, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Hospital Povisa, Vigo, Spain; Roche Farma, S.A., Madrid, Spain
| |
Collapse
|
38
|
Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J. Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with advanced NSCLC other than predominantly squamous cell histology. B has been shown to improve progression free survival (PFS) and overall survival (OS) when combined with cisplatin/gemcitabine and carboplatin/paclitaxel, respectively. However, there are limited data on the safety and efficacy of B in combination with other widely used chemotherapy doublets for NSCLC. This is a single-arm, open- labeled, single-stage phase II trial of cisplatin (C), docetaxel (D) and B for NSCLC. Methods: Eligibility criteria: chemo- naïve, stage IIIB wet or IV, non-squamous NSCLC, PS 0–1, no brain metastases and no history of gross hemoptysis. P received D (75 mg/m2), C (75 mg/m2), and B (15 mg/kg iv) on day 1 every 3 weeks for up to 6 cycles, followed by B 15 mg/kg alone every 3 weeks until disease progression or toxicity. Primary endpoint: PFS. Results: 50 p were enrolled (enrollment completed): 24% female, median age 60 (36–74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 92%. Two p did not start treatment. Median follow-up is 5.3 months (range 0–13.6). Median number of cycles of B was 7 (range 0–18). 56% completed 6 cycles of treatment; 24% received ≥ 12 cycles of B. Most frequent grade ≥ 3 toxicities: diarrhea (14.6%), fatigue (14.6%), dyspnea (9.8%), anorexia (4.9%), alopecia (4.9%), esophagitis (4.9%), constipation (4.9%), mucositis (12.2%), proteinuria (4.9%); hematological toxicities: neutropenia (22%), febrile neutropenia (9.8%), leucopenia (14.6%), lymphopenia (4.9%). Of interest, 41.5% developed grade <3 epistaxis and 17% hypertension (1 p grade 3). One p died due to hemoptysis. 46 p were evaluable for response: 29 PRs (ORR: 63%). 18 of 48 p have experienced progression or death with a median SLP of 7.8 months (95% CI: 6.6-NR). Median OS is 13.5 months (95% CI: 12.7–13.6; 81.2% p censored); 1-year survival is 83.9% (95% CI: 67.4%-92.5%). Conclusions: Treatment with C, D and B, followed by maintenance B in 1st line of advanced non-squamous NSCLC shows an acceptable toxicity profile and promising efficacy. Final results will be presented. [Table: see text]
Collapse
Affiliation(s)
- N. Ferrer
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - M. Cobo
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - A. Paredes
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - M. Méndez
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - J. Muñoz-Langa
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - A. Rueda
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - M. Álvarez de Mon
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - A. Sánchez-Hernández
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - R. Gallego
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| | - J. Torrego
- Hospital Son Llàtzer, Palma de Mallorca, Spain; Hospital Regional Universitario Carlos Haya, Málaga, Spain; Hospital Donostia, San Sebastián, Spain; Hospital Universitario de Móstoles, Móstoles, Spain; Hospital Universitario Dr. Peset, Valencia, Spain; Hospital Universitario Puerta del Mar, Cádiz, Spain; Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Hospital Provincial de Castellón, Castellón, Spain; Roche Farma, S.A., Madrid, Spain; Hospital Universitario Río Hortega, Valladolid
| |
Collapse
|
39
|
Pera M, Gallego R, Martin-Richard M, Montagut C, Iglesias M, Conill C, Balaguer C, Petriz L, Momblan D, Maurel J. Phase II study with preoperative oxaliplatin (O), cisplatin (P), 5-fluorouracil (F) (OPF) and radiation (XRT) in patients with esophageal (ES), gastroesophageal (GE), and gastric (G) cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15612 Background: A phase I study showed the feasibility of the triplet combination (OPF) with XRT in ES and GE cancer (Maurel et al, IJRBOP, 2005). We conducted a phase II study to evaluate the efficacy of the regimen. Methods: Enrolled pts had resectable, high-risk (HR) based on endoscopic ultrasonography (EUS) (uT3, uN1 or uT4 if deemed resectable) ES, GE and G cancer. The primary objective was to determine the pathologic complete response (pCR). If 2 or more pCR were reported in the first 18 pts treated, enrollment continues with 23 additional pts. Eligibility criteria: squamous cell or adenocarcinoma of the ES, GE or G cancer and ECOG Performance status (PS) 0–1. Staging was done with EUS and computed spiral tomography. Laparoscopic staging was mandatory for pts with ES, GE and G adenocarcinoma. Pts received 2 cycles of O 85 mg/m2, P 55 mg/m2, F (3 g/m2 in 96h CI) q4w, with concomitant 45 Gy XRT in 25 fractions; surgery was planned 5–8 weeks after XRT. All pathological specimens were reviewed by a unique pathologist and regression analysis was recorded using Cologne (C) and M.D.Anderson (MDA) classification for ES and European Journal of Surgical Oncology (EJSO) for GE and G. Results: Between 5/04 to 12/07, 41 pts were enrolled in 5 Spanish Institutions. Median age 62 yrs (39–75 yrs); Male/female 83%/17%; PS 0/1 27%/73%; ES/GE/G 39%/32%/29%; EUS stageT3N0 (20%), T2–3N1 (65%) and T4 (10%). G3/4 adverse events included asthenia (27%), infection (7%), diarrhea (7%) and stomatitis (5%). There were 2 toxic deaths. Of the 31 pts who underwent surgery, there were R0=94%/R1=3%/R2= 3%. 7/41 pts (17%) achieved pCR. Using C and MDA classification, 9/14 (61%) and 12/14 (85%) ES achieved grade IV/III and P0/P1 regression, respectively. With EJSO classification 3/17 (18%) GE and G tumors achieved pCR. Median time to progression or death (PFS) was 16.2 (CI:12.2-NR) months (mo). Median overall survival (OS) was 28.9 mo. (CI: 22.5-NR). Conclusions: Although in the whole group pCR, PFS and OS does not appear superior to results achieved in other trials with preoperative P/F/XRT in HR pts, the OPF regimen seems specially active in ES cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Pera
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - R. Gallego
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - M. Martin-Richard
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - C. Montagut
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - M. Iglesias
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - C. Conill
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - C. Balaguer
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - L. Petriz
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - D. Momblan
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| | - J. Maurel
- Hospital Universitario del Mar, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital de Sant Pau, Barcelona, Spain
| |
Collapse
|
40
|
Sanchez B, Relova JL, Gallego R, Ben-Batalla I, Perez-Fernandez R. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res 2009; 87:723-32. [PMID: 18816795 DOI: 10.1002/jnr.21878] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
It has previously been demonstrated that 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] administration, whether in cell cultures or in vivo to rats, increases glial cell line-derived neurotrophic factor (GDNF) expression levels, suggesting that this hormone may have beneficial effects in neurodegenerative disorders. This study was carried out to explore the effects of 1,25(OH)(2)D(3) administration in a 6-OHDA-lesioned rat model of Parkinson's disease on GDNF and tyrosine hydroxylase (TH) expression in substantia nigra (SN) and striatum. Two groups of animals received 1,25(OH)(2)D(3) intraperitoneally, the first group 7 days before the unilateral injection of 6-OHDA into the medial forebrain bundle (MFB) and the second group 21 days (days 21-28) after the unilateral injection of 6-OHDA. Animals of both groups were sacrificed on day 28. In addition, two other groups received a unilateral injection of either saline or 6-OHDA into the MFB. Rats were killed, and the SN and striatum were then removed for GDNF and TH determination. Striatal GDNF protein expression was increased on the ipsilateral with respect to the contralateral side after 6-OHDA injection alone as well as in 1,25(OH)(2)D(3)-treated rats before or after 6-OHDA administration. As expected, 6-OHDA injection induced an ipsilateral decrease in TH-immunopositive neuronal cell bodies and axonal terminals in the SN and striatum. However, treatment with 1,25(OH)(2)D(3) before and after 6-OHDA injection partially restored TH expression in SN. These data suggest that 1,25(OH)(2)D(3) may help to prevent dopaminergic neuron damage.
Collapse
Affiliation(s)
- Begoña Sanchez
- Department of Physiology, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | | | | |
Collapse
|
41
|
Landin L, Cavadas PC, Nthumba P, Muñoz G, Gallego R, Belloch V, Avila C, Loro M, Ibañez J, Roger I, Linares-Martinez N. Morphological and functional evaluation of visual disturbances in a bilateral hand allograft recipient. J Plast Reconstr Aesthet Surg 2009; 63:700-4. [PMID: 19237332 DOI: 10.1016/j.bjps.2008.12.033] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2008] [Accepted: 12/22/2008] [Indexed: 12/22/2022]
Abstract
Allograft recipients are exposed to risks owing to immunosuppression, and there is always the possibility that psychological issues interfere with the procedure's outcomes. An episode of blindness was suspected in a bilateral hand allograft recipient. The patient underwent a multidisciplinary evaluation, and clinical, electrophysiological, laboratory and a combination of functional and morphological magnetic resonance imaging (MRI) tests ruled out any visual process and revealed a secondary benefit, which turned out to be the use of privileges of the transplant support centre for several months. Composite tissue allograft recipients require a thorough psychological assessment before and after transplant procedures to prevent malingering.
Collapse
Affiliation(s)
- L Landin
- Plastic & Reconstructive Surgery Division, La Fe University Hospital, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Berruga M, Rodriguez A, Rubio R, Gallego R, Molina A. Short Communication: Antibiotic Residues in Milk Following the Use of Intravaginal Sponges for Estrus Synchronization in Dairy Ewes. J Dairy Sci 2008; 91:3917-21. [DOI: 10.3168/jds.2008-1085] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
43
|
Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ, Gualillo O. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 2008; 16:1101-9. [PMID: 18261936 DOI: 10.1016/j.joca.2007.12.008] [Citation(s) in RCA: 188] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2007] [Accepted: 12/22/2007] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Recent studies revealed a close connection between adipose tissue, adipokines and articular degenerative inflammatory diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA). The goal of this work was to investigate the activity of adiponectin in human and murine chondrocytes and to study its functional role in the modulation of nitric oxide synthase type II (NOS2). For completeness, interleukin (IL)-6, IL-1beta, matrix metalloproteinase (MMP)-2, MMP-3, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, prostaglandin E2 (PGE2), leukotriene B4 (LTB4), tumor necrosis factor alpha (TNF)-alpha and monocyte chemoattractant protein-1 (MCP-1) accumulation have been evaluated in adiponectin-stimulated chondrocytes cell culture supernatants. METHODS Murine ATDC5 cell line, C28/I2, C20A4, TC28a2 human immortalized chondrocytes, and human cultured chondrocytes were used. Nitrite accumulation was determined by Griess reaction. Adiponectin receptors (AdipoRs) expression was evaluated by immunofluorescence microscopy and confirmed by reverse transcriptase-polymerase chain reaction. NOS2 expression was evaluated by Western blot analysis whereas cytokines, prostanoids and metalloproteinases production was evaluated by specific enzyme-linked immunosorbent assays. RESULTS Human and murine chondrocytes express functional AdipoRs. Adiponectin induces NOS2. This effect is inhibited by aminoguanidine, dexamethasone and by a selective inhibitor of phosphatidylinositol 3-kinase. In addition, adiponectin is able to increase IL-6, MMP-3, MMP-9 and MCP-1 by murine cultured chondrocytes whereas it was unable to modulate TNF-alpha, IL-1beta, MMP-2, TIMP-1, PGE2 and LTB4 release. CONCLUSIONS These results bind more closely the interactions between fat-derived adipokines and articular inflammatory diseases, and suggest that adiponectin is a novel key element in the maintenance of cartilage homeostasis which might be considered as a potential therapeutical target in joint degenerative diseases.
Collapse
Affiliation(s)
- R Lago
- Santiago University Clinical Hospital, Research Laboratory 4, NeuroEndocrine Interactions in Rheumatology and Inflammatory Diseases Laboratory, Santiago de Compostela, Spain
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Ferrer N, Paredes A, Muñoz-Langa JM, Mendez M, Cobo M, de-Portugal T, Giner V, Garcia S, Gallego R, Torrego J. Bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (pts) with advanced or metastatic, non squamous, non-small-cell lung cancer (NSCLC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Gallego R, Garcia-Albeniz X, Codony-Servat J, Nadal C, Carcereny E, Longaron R, Augé J, Gascón P, Maurel J. Correlation of matrilysin levels and IGF-1/IGFBP-3 ratio with acquired chemo-resistance in advanced colorectal cancer (ACRC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Augé J, Gallego R, Tosca M, Gascón P, Maurel J. Pharmacodynamic study of soluble FAS (sFAS) and FASL (sFASL), in patients (pts) with advanced colorectal cancer (ACRC) after irinotecan and cetuximab treatment in third-line therapy: Results of HCB-05–01 trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Carcereny E, Castellvi-Bel S, Alonso V, Garcia-Albeniz X, Muñoz J, Gallego R, Hondler C, Castells A, Gascón P, Maurel J. EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4124] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Vega ND, Gallego R, Oliva E, Henriquez F, Palop L, Divino Filho JC, Lindholm B. Nocturnal ultrafiltration profiles in patients on APD: impact on fluid and solute transport. Kidney Int 2008:S94-S101. [PMID: 18379556 DOI: 10.1038/sj.ki.5002609] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In order to prevent morbidity and mortality in peritoneal dialysis (PD), sodium and water balance as well as a minimal level of small-solute clearances are needed. The impact of three nocturnal peritoneal ultrafiltration (UF) profiles on UF and small solute clearance in patients on automated PD (APD) was studied: constant glucose concentration of 1.36% (flat) or modifying the glucose concentration of the heater bag (descendant: 3.86-1.36%; ascendant: 1.36-3.86%). Sixty-two patients were enrolled in the study and received each profile within a four-month period, thus serving as their own controls. UF was lower with the flat profile (367+/-420ml; P<0.01), but no difference was seen between the two higher glucose concentration profiles. Peritoneal Kt/V (pKt/V) and peritoneal creatinine clearance (CrpC) showed statistically higher values from the descendant vs ascendant vs flat profiles (pKt/V: 1.54+/-0.30 vs 1.45+/-0.30 vs 1.38+/-0.27, and CrpC: 36.9+/-7.9 vs 33.5+/-7.48 vs 29.92+/-7.5 mlmin(-1)). Multivariate analysis showed statistical significance for the following: in the intrasubject comparisons, the profile for pKt/V (F=9.109, P<0.001) and CrpC (F=11.697, P<0.001), and in the intersubjects comparisons, the effects of both gender (F=14.334, P<0.01) for pKt/V and peritoneal permeability for both parameters (pKt/V: F=4.37, P<0.05; CrpC: F=11.697, P<0.001). In conclusion, the application of ascendant and descendant UF profiles in automated PD is feasible and results in better UF and small solute clearances, thus preventing inadequate dialysis and volume overload..
Collapse
Affiliation(s)
- N D Vega
- Division of Nephrology, Hospital, Universitario de Gran Canaria Dr Negrín, Canary Islands, Spain.
| | | | | | | | | | | | | |
Collapse
|
49
|
Gallego R, García-López D, López-Quintana S, Gobernado-Mitre I, Merino JC, Pastor JM. Toughening of PA6/mEPDM Blends by two Methods of Compounding, Extruder and Internal Mixer: Rheological, Morphological and Mechanical Characterization. Polym Bull (Berl) 2008. [DOI: 10.1007/s00289-008-0902-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Gallego R, García-López D, López-Quintana S, Gobernado-Mitre I, Merino JC, Pastor JM. Influence of blending sequence on micro- and macrostructure of PA6/mEPDM/EPDMgMA blends reinforced with organoclay. J Appl Polym Sci 2008. [DOI: 10.1002/app.28141] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|